SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Sonoma Pharmaceuticals, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.12+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $4.31M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
38.0%+2.8 pts over 5 years
Operating margin
-12.6%+5.9 pts over 5 years
Net margin
-16.3%+4.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +36.7% | +13.7% | +0.9% | +7.6% | |
| Gross profit | +35.7% | +18.3% | +2.5% | +10.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 58.8% | -71.9% | -84.6% | |
| Return on assets | 47.2% | -26.7% | -23.0% | |
| Current ratio | 6.89 | 3.18 | 2.50 | |
| Debt to equity | 0.01 | 0.36 | – | |
| Net debt to EBITDA | 1.36× | 0.72× | – | |
| Interest coverage | -4324.7× | -287.4× | – | |
| Inventory turnover | 3.8× | 5.1× | 3.7× | |
| Capex to revenue | 3.1% | 1.0% | 1.0% | |
| Diluted shares | 0M | 0M | 2M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Sonoma Pharmaceuticals generated $16.82M from operations and spent $680.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$16.82M
Used
$680.00K
Capital expenditure$680.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-16.3%
×Asset turnover1.41×
×Equity multiplier3.68×
=Return on equity, FY2026-84.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -16.3% | 1.41× | 3.68× | -84.6% |
| FY2025 | -24.2% | 1.01× | 2.70× | -65.5% |
| FY2024 | -38.0% | 0.82× | 2.19× | -68.5% |
| FY2023 | -38.8% | 0.76× | 2.10× | -61.8% |
| FY2022 | -40.3% | 0.75× | 2.41× | -72.3% |
| FY2021 | -21.2% | 1.26× | 2.69× | -71.9% |
| FY2020 | -18.5% | 1.24× | 2.17× | -49.4% |
| FY2019 | -62.2% | 1.13× | 1.46× | -102.2% |
| FY2018 | -86.0% | 0.75× | 1.22× | -78.0% |
| FY2017 | 72.3% | 0.65× | 1.24× | 58.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$3.18M
- Cash generatingOperating cash flow above zero-$3.93M
- Return on assets improvedROA up on the prior year-23.5% → -23.2%
- Earnings backed by cashOperating cash flow above net income-$3.93M vs -$3.18M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.09 → 2.50
- No dilutionShare count did not rise1M → 2M
- Gross margin improvedGross margin up on the prior year38.25% → 37.97%
- More efficientAsset turnover rose0.97 → 1.43